A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients. - Wikidata - awgldk - TriplyDB

A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.

A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.

http://www.wikidata.org/entity/Q33399656

about

Emerging new therapeutic applications of capecitabine as a first-line chemotherapeutic agent in the management of advanced carcinomas other than colorectal carcinoma.Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.

P2860

Q42181037-416D7F63-9A49-44F9-9629-15EB85A9C451 Q50609881-9F40C5A2-AE62-4EE6-BD01-C6A595E6E77C

P2860

A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.

http://www.wikidata.org/entity/Q33399656

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

A phase II trial of fixed-dose ...... biliary tract cancer patients.

@ast

A phase II trial of fixed-dose ...... biliary tract cancer patients.

@en

type

label

A phase II trial of fixed-dose ...... biliary tract cancer patients.

@ast

A phase II trial of fixed-dose ...... biliary tract cancer patients.

@en

prefLabel

A phase II trial of fixed-dose ...... biliary tract cancer patients.

@ast

A phase II trial of fixed-dose ...... biliary tract cancer patients.

@en

P1433

Q33399656-3D83A3D5-8896-44F9-8AA9-A44DC677376B

P1476

Q33399656-3074A8CC-7BB0-4F26-91D2-35257BBC2884

P2093

Q33399656-39A4A30B-DBC5-4AC7-BD18-3D6E11FCE586

Q33399656-423CE4DE-7541-4503-82DA-EAF6ADA186A3

Q33399656-5F35F9C2-EBD1-48BA-AA92-90533517D1F8

Q33399656-87E93EB7-F480-4777-95BD-F909E39182AE

Q33399656-944E08D7-E607-4F00-8CD4-C98A61A54BE2

Q33399656-9476CDC6-F040-456D-8BB7-740BDFB0CDBD

Q33399656-F756F7FC-59CE-48F8-B532-E5BC54720567

P2860

Q33399656-090D00BA-A247-44FA-91E4-F1D82F6DB8D6

Q33399656-0AFF317C-1C06-40CF-90E9-4E195731D06A

Q33399656-13C2BA3D-2809-4B2C-A031-32FF07884CC9

Q33399656-19221A81-9786-43AA-A16C-150995B74A34

Q33399656-25429CA7-791F-4D16-81E7-D1A1C5957144

Q33399656-257E15B9-2456-4E31-BD7B-C9E162ED7854

Q33399656-263F75EF-43D9-415F-A884-1E12D26106FE

Q33399656-34BE03AF-880C-48FB-A5B2-580C3E3DD230

Q33399656-35E4BD99-8785-434A-83E5-8A7648294D46

Q33399656-3A1483F5-80BC-4FD4-A056-F248B0C2F00C

P304

Q33399656-D3FFF4AC-6388-4283-B35D-ED13122D94B8

P31

Q33399656-FB635158-FFC5-4D26-88F6-9CD0D1073E1A

P356

Q33399656-03E01CB5-C353-4618-B108-EF6AC8FDC03C

P433

Q33399656-056B2968-120D-4ADE-B74D-00E76B1896E7

P478

Q33399656-E847C907-7A0C-4F95-8871-EEFD1A366250

P50

Q33399656-4953A3B9-F7C6-4E8B-A26E-604205652A91

Q33399656-6C8B05D0-EF95-45A0-9177-8B5EB965816C

Q33399656-85D02EE5-9081-4511-A85E-3D50FB418D58

Q33399656-90A654CC-5EFF-410B-9778-DB1F1446297B

P577

Q33399656-EF9EAA6B-CD8C-45E4-8EE9-0E7792EBE914

P5875

Q33399656-187302B9-8418-4B41-AF7B-A1C6893DB768

P698

Q33399656-ADE47593-DDC6-4C9A-B6A1-2A535D55C554

P921

Q33399656-34A1B326-3644-4C0C-A14A-7CE9F85BFCC2

P356

P1433

P1476

A phase II trial of fixed-dose ...... biliary tract cancer patients.

@en

P2093

Antonio Russo

http://www.w3.org/2001/XMLSchema#string

Enrico Vasile

http://www.w3.org/2001/XMLSchema#string

Francesco Graziano

http://www.w3.org/2001/XMLSchema#string

Gianluca Masi

http://www.w3.org/2001/XMLSchema#string

Giuseppe Bronte

http://www.w3.org/2001/XMLSchema#string

Vincenzo Catalano

http://www.w3.org/2001/XMLSchema#string

Vladimir Virzi

http://www.w3.org/2001/XMLSchema#string

P2860

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

A phase II study of gemcitabine in gallbladder carcinoma.

Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.

Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.

P304

75-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000329079

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P50

Daniele Santini

Giuseppe Tonini

Alfredo Falcone

P577

2012-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221826196

http://www.w3.org/2001/XMLSchema#string

P698

22327844

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial